Zevra Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Zevra Therapeutics (ZVRA) with a Buy rating and $26 price target Zevra has successfully launched Miplyffa for Niemann-Pick disease type C in the U.S. and the firm sees “multiple levers for further long term value creation,” the analyst tells investors. Even with the success of Miplyffa in the U.S., the firm believes the stock “remains undervalued on the Miplyffa U.S. opportunity alone,” the analyst added.